| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer GV Scagliotti, P Parikh, J Von Pawel, B Biesma, J Vansteenkiste, ... Journal of clinical oncology 26 (21), 3543-3551, 2008 | 4279 | 2008 |
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer GV Scagliotti, P Parikh, J Von Pawel, B Biesma, J Vansteenkiste, ... Journal of clinical oncology 26 (21), 3543-3551, 2008 | 4279 | 2008 |
| The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 | 3979 | 2016 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2851 | 2019 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1526 | 2019 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1379 | 2014 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 511 | 2019 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 430 | 2021 |
| The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer K Chansky, FC Detterbeck, AG Nicholson, VW Rusch, E Vallières, ... Journal of Thoracic Oncology 12 (7), 1109-1121, 2017 | 405 | 2017 |
| The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung … AG Nicholson, K Chansky, J Crowley, R Beyruti, K Kubota, A Turrisi, ... Journal of Thoracic Oncology 11 (3), 300-311, 2016 | 377 | 2016 |
| The European Organization for Research and Treatment of Cancer QLQ‐C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ‐C30 A Guzelant, T Goksel, S Ozkok, S Tasbakan, T Aysan, A Bottomley European journal of cancer care 13 (2), 135-144, 2004 | 240 | 2004 |
| The IASLC lung cancer staging project: methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming … FC Detterbeck, K Chansky, P Groome, V Bolejack, J Crowley, ... Journal of thoracic oncology 11 (9), 1433-1446, 2016 | 223 | 2016 |
| Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trial R Ramlau, V Gorbunova, TE Ciuleanu, S Novello, M Ozguroglu, T Goksel, ... Journal of Clinical Oncology 30 (29), 3640-3647, 2012 | 201 | 2012 |
| The IASLC lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming … FC Detterbeck, AG Nicholson, WA Franklin, EM Marom, WD Travis, ... Journal of Thoracic Oncology 11 (5), 639-650, 2016 | 199 | 2016 |
| Rapid point-of-care COVID-19 diagnosis with a gold-nanoarchitecture-assisted laser-scribed graphene biosensor T Beduk, D Beduk, JI de Oliveira Filho, F Zihnioglu, C Cicek, R Sertoz, ... Analytical chemistry 93 (24), 8585-8594, 2021 | 140 | 2021 |
| Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial Y Cheng, L Han, L Wu, J Chen, H Sun, G Wen, Y Ji, M Dvorkin, J Shi, ... Jama 328 (12), 1223-1232, 2022 | 136 | 2022 |
| Higher airborne pollen concentrations correlated with increased SARS-CoV-2 infection rates, as evidenced from 31 countries across the globe A Damialis, S Gilles, M Sofiev, V Sofieva, F Kolek, D Bayr, MP Plaza, ... Proceedings of the National Academy of Sciences 118 (12), e2019034118, 2021 | 125 | 2021 |
| The IASLC lung cancer staging project: background data and proposals for the classification of lung cancer with separate tumor nodules in the forthcoming eighth edition of the … FC Detterbeck, V Bolejack, DA Arenberg, J Crowley, JS Donington, ... Journal of Thoracic Oncology 11 (5), 681-692, 2016 | 109 | 2016 |
| İzmir ili lise öğrencilerinin sigara alışkanlığını etkileyen faktörler T Göksel, M Cirit, Ü BAYINDIR Toraks dergisi 2 (3), 49-53, 2001 | 96 | 2001 |
| Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit … GV Scagliotti, K Park, S Patil, J Rolski, T Goksel, R Martins, SJM Gans, ... European Journal of Cancer 45 (13), 2298-2303, 2009 | 78 | 2009 |
